Sotyktu

Sotyktu (deucravacitinib) treats psoriasis by selectively targeting the immune system by inhibiting tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family. Sotyktu is approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

What is Sotyktu?

How Is It Used?

Sotykty is taken once-daily by mouth.

What are the most common adverse reactions?

The most common adverse reactions (≥1%) are upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, and acne.

Three men near a car, one sitting in the driver seat with the door open.

FDA Approves Sotyktu™ for Psoriasis

A new oral treatment option for adults with plaque psoriasis.

Read Article

Psoriasis 101

Newly diagnosed? Want a refresher? Dr. Jason E. Hawkes is here to break down the science of psoriatic disease.

Learn More
A smiling doctor hands her patient a prescription in an office.

Provider Directory

Find the health care provider that is right for you.

Read Article

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logoTwill Care logo

Copyright © 1996-2022 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.